From a clinical perspective, genes such as RBP4 and FNDC5 could serve as promising biomarkers for the early detection and monitoring of metabolic–muscular dysfunction in both sarcopenia and T2DM. This evidence concerns the gene FNDC5 and type 2 diabetes mellitus.